The monoclonal antibody trastuzumab and the small-molecule tyrosine kinase inhibitor lapatinib are the first two HER2-targeted therapies approved by the U.S. Food and Drug Administration for treatment of patients with HER2-overexpressing breast cancer [3-5]. The gene discussed is ERBB2; the disease is breast cancer.